Skip to main content
. 2018 Jan 11;14(1):47–56. doi: 10.7150/ijbs.22209

Table 2.

The association of SHP2 mRNA level with the response to TKI therapy in lung adenocarcinoma patients.

The response to TKI therapy
Variables Patient No. Unfavorable (%) Favorable (%) P
SHP2
Low 18 7 (39) 11 (61) 0.044
High 18 13 (72) 5 (28)

The unfavorable response is defined at least 25% increase in size or number of the tumors; otherwise is defined as a favorable response. The median value of SHP2 mRNA levels was used as cutoff point to divide patients into “high” and “low” subgroups.